XML 65 R53.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting - Schedule of Segment Revenue, Loss and Significant Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Collaboration revenue $ 22,263   $ 10,971   $ 50,034 $ 18,150
General and administrative 10,609   9,295   24,739 21,633
Total operating expenses 48,433   51,292   103,743 100,672
Loss from operations (26,170)   (40,321)   (53,709) (82,522)
Interest income 3,654   4,623   8,067 9,207
Non-cash interest expense (19,606)   (10,953)   (37,667) (17,270)
Other income (expense), net 3,531   0   5,433 (2)
Total other expense, net (12,421)   (6,330)   (24,167) (8,065)
Loss before income taxes (38,591)   (46,651)   (77,876) (90,587)
Provision for income taxes (39)   (9)   (83) (9)
Segment net loss (38,630) $ (39,329) (46,660) $ (43,936) (77,959) (90,596)
Reportable Segment            
Segment Reporting Information [Line Items]            
Collaboration revenue 22,263   10,971   50,034 18,150
Research and development 37,824   41,997   79,004 79,039
General and administrative 10,609   9,295   24,739 21,633
Total operating expenses 48,433   51,292   103,743 100,672
Loss from operations (26,170)   (40,321)   (53,709) (82,522)
Interest income 3,654   4,623   8,067 9,207
Non-cash interest expense (19,606)   (10,953)   (37,667) (17,270)
Other income (expense), net 3,531   0   5,433 (2)
Total other expense, net (12,421)   (6,330)   (24,167) (8,065)
Loss before income taxes (38,591)   (46,651)   (77,876) (90,587)
Provision for income taxes (39)   (9)   (83) (9)
Segment net loss (38,630)   (46,660)   (77,959) (90,596)
Reportable Segment | External            
Segment Reporting Information [Line Items]            
Research and development 25,176   30,596   52,765 56,405
General and administrative 2,436   2,330   7,976 4,451
Reportable Segment | Rosnilimab            
Segment Reporting Information [Line Items]            
Research and development 15,614   12,926   30,639 22,965
Reportable Segment | ANB033            
Segment Reporting Information [Line Items]            
Research and development 3,925   2,982   7,729 5,645
Reportable Segment | ANB101            
Segment Reporting Information [Line Items]            
Research and development 2,040   544   3,521 944
Reportable Segment | ANB032            
Segment Reporting Information [Line Items]            
Research and development 108   7,584   3,644 12,451
Reportable Segment | Imsidolimab            
Segment Reporting Information [Line Items]            
Research and development (967)   1,867   (1,156) 6,363
Reportable Segment | Preclinical and other unallocated costs            
Segment Reporting Information [Line Items]            
Research and development 4,456   4,693   8,388 8,037
Reportable Segment | Internal            
Segment Reporting Information [Line Items]            
Research and development 12,648   11,401   26,239 22,634
General and administrative $ 8,173   $ 6,965   $ 16,763 $ 17,182